Date: 2015-05-26
Type of information: Development agreement
Compound: chimeric antigen receptor (CAR) T cell therapies
Company: Bluebird bio (USA - MA) Five Prime Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: development commercialisation
Action mechanism: cell therapy/gene therapy
Disease: hematologic malignancies, solid tumors
Details: * On May 26, 2015, bluebird bio and Five Prime Therapeutics announced that they have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies using Five Prime’s proprietary human antibodies to an undisclosed cancer target for hematologic malignancies and solid tumors. Under the terms of the agreement, Five Prime will provide bluebird bio exclusive rights to its novel human antibodies to the target, and bluebird bio will leverage its proprietary lentiviral gene therapy platform and CAR T capabilities to develop CAR T therapies against the target.
Financial terms: Financial terms of the agreement include a $1.5 million upfront payment and subsequent milestone payments to Five Prime, which together could total over $130 million per licensed product if certain development, regulatory, and commercial milestones are achieved. Five Prime is also eligible to receive tiered royalties on product sales. bluebird bio will conduct and fund clinical development as well as regulatory and commercial activities.
Latest news:
